| 61.05 -1.38 (-2.21%) | 08-28 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 74.96 | 1-year : | 87.55 |
| Resists | First : | 64.18 | Second : | 74.96 |
| Pivot price | 59.46  |
|||
| Supports | First : | 56.2 | Second : | 51.27 |
| MAs | MA(5) : | 62.49 |
MA(20) : | 58.34 |
| MA(100) : | 68.9 |
MA(250) : | 72.51 |
|
| MACD | MACD : | 0.5 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 80 |
D(3) : | 88.2 |
| RSI | RSI(14): 53.2 |
|||
| 52-week | High : | 86.73 | Low : | 49.13 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ IONS ] has closed below upper band by 34.8%. Bollinger Bands are 8.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 61.82 - 62.19 | 62.19 - 62.47 |
| Low: | 59.46 - 59.96 | 59.96 - 60.32 |
| Close: | 60.4 - 61.13 | 61.13 - 61.67 |
Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapies within the United States. Its commercial portfolio includes three key medications: SPINRAZA, prescribed for spinal muscular atrophy (SMA) in both children and adults; TEGSEDI, an injectable treatment targeting polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adult patients; and WAYLIVRA, which addresses familial chylomicronemia syndrome and familial partial lipodystrophy. Ionis also maintains a robust pipeline, with several drug candidates currently in Phase 3 clinical trials. These include Eplontersen, a monthly self-administered subcutaneous injection designed for all forms of TTR amyloidosis; Olezarsen, intended for individuals with severe hypertriglyceridemia (SHTG); Donidalorsen, for patients suffering from hereditary angioedema; ION363, aimed at amyotrophic lateral sclerosis (ALS); Pelacarsen, developed for those with established cardiovascular disease and elevated lipoprotein(a); and Tofersen, which works by inhibiting the production of superoxide dismutase 1. Beyond these late-stage assets, the company is actively researching treatments for metabolic, infectious, renal, and ophthalmic diseases, as well as various types of cancer. The firm engages in significant collaborations, notably a strategic partnership with Biogen Inc. Additionally, it holds licensing and collaboration agreements with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc.
Fri, 28 Aug 2026
Could Ionis Pharmaceuticals (IONS) Stock Become a Biotech Powerhouse as its Commercial Pipeline Takes Off? - Yahoo Finance
Mon, 24 Aug 2026
Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis: Navigating a 47% Upside Potential Amidst Challenges - DirectorsTalk Interviews
Fri, 21 Aug 2026
The Bull Case For Ionis Pharmaceuticals (IONS) Could Change Following New ESC 2026 RNA Data Package – Learn Why - Sahm
Mon, 17 Aug 2026
Ionis Pharma (IONS): FDA Catalysts, Accelerating Revenue And A Path To 2028 Cash-flow Breakeven - RTTNews
Thu, 06 Aug 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS - PR Newswire
Tue, 04 Aug 2026
Michael Hayden Bought 34% More Shares In Ionis Pharmaceuticals - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 166 (M) |
| Shares Float | 165 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 110.3 (%) |
| Shares Short | 21,470 (K) |
| Shares Short P.Month | 17,430 (K) |
| EPS | -3.49 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.65 |
| Profit Margin | -64.7 % |
| Operating Margin | -38.2 % |
| Return on Assets (ttm) | -12.5 % |
| Return on Equity (ttm) | -105.5 % |
| Qtrly Rev. Growth | -40.8 % |
| Gross Profit (p.s.) | -0.37 |
| Sales Per Share | 5.25 |
| EBITDA (p.s.) | -3.49 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -496 (M) |
| Levered Free Cash Flow | -347 (M) |
| PE Ratio | -17.55 |
| PEG Ratio | 27.3 |
| Price to Book value | 23.03 |
| Price to Sales | 11.6 |
| Price to Cash Flow | -20.44 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|